Key result
Substrate-based ablation reduces 12-month VT recurrence by ~33 percentage points over clinical VT ablation.
Why the study?
Catheter ablation reduces VT recurrence and ICD shocks in ischemic cardiomyopathy, but the most effective catheter ablation technique is unknown.
Does substrate-based ablation reduce VT recurrence compared to clinical VT ablation in patients with ischemic cardiomyopathy and hemodynamically tolerated VT?
RCT (n=118)
Randomized
Yes
Does substrate-based ablation reduce VT recurrence compared to clinical VT ablation in patients with ischemic cardiomyopathy and hemodynamically tolerated VT?
In patients with ischemic cardiomyopathy and tolerated VT, an extensive substrate-based ablation approach significantly reduces VT recurrence compared to ablation targeting only clinical and stable VTs.
Answers are grounded in this paper and cite their sources.
Substrate ablation in ischemic VT was associated with fewer recurrences; leaves open optimal strategy pending randomized confirmation.
Ablation of Stable VTs Versus Substrate Ablation in Ischemic Cardiomyopathy the VISTA Randomized Multicenter Trial Di Biase, Luigi; Burkhardt, J. David; Lakkireddy, Dhanujaya; Carbucicchio, Corrado; Mohanty, Sanghamitra; Mohanty, Prasant; Trivedi, Chintan; Santangeli, Pasquale; Bai, Rong; Forleo, Giovanni; Horton, Rodney; Bailey, Shane; Sanchez, Javier; Al-Ahmad, Amin; Hranitzky, Patrick; Gallinghouse, G. Joseph; Pelargonio, Gemma; Hongo, Richard H.; Beheiry, Salwa; Hao, Steven C.; Reddy, Madhu; Rossillo, Antonio; Themistoclakis, Sakis; Dello Russo, Antonio; Casella, Michela; C. Tondo Penultimo ; A. Natale Ultimo 2015 Abstract Background Catheter ablation reduces ventricular tachycardia (VT) recurrence and implantable cardioverter defibrillator shocks in patients with VT and ischemic cardiomyopathy. The most effective catheter ablation technique is unknown. Objectives This study determined rates of VT recurrence in patients undergoing ablation limited to clinical VT along with mappable VTs ("clinical ablation") versus substrate-based ablation. Methods Subjects with ischemic cardiomyopathy and hemodynamically tolerated VT were randomized to clinical ablation (n = 60) versus substrate-based ablation that targeted all "abnormal" electrograms in the scar (n = 58). Primary endpoint was recurrence of VT. Secondary endpoints included periprocedural complications, 12-month mortality, and rehospitalizations. Results At 12-month follow-up, 9 (15.5%) and 29 (48.3%) patients had VT recurrence in substrate-based and clinical VT ablation groups, respectively (log-rank p < 0.001). More patients undergoing clinical VT ablation (58%) were on antiarrhythmic drugs after ablation versus substrate-based ablation (12%; p < 0.001). Seven (12%) patients with substrate ablation and 19 (32%) with clinical ablation required rehospitalization (p = 0.014). Overall 12-month mortality was 11.9%; 8.6% in substrate ablation and 15.0% in clinical ablation groups, respectively (log-rank p = 0.21). Combined incidence of rehospitalization and mortality was significantly lower with substrate ablation (p = 0.003). Periprocedural complications were similar in both groups (p = 0.61). Conclusions An extensive substrate-based ablation approach is superior to ablation targeting only clinical and stable VTs in patients with ischemic cardiomyopathy presenting with tolerated VT.
No takes yet. Share an insight, caveat, or question.
Biase et al. (2015) conducted an RCT in Ischemic cardiomyopathy and hemodynamically tolerated ventricular tachycardia (n=118). Substrate-based ablation targeting all abnormal electrograms in the scar vs. Clinical ablation limited to clinical VT along with mappable VTs was evaluated on Recurrence of ventricular tachycardia at 12 months (p=< 0.001). Substrate-based ablation was superior to clinical VT ablation in reducing 12-month VT recurrence in patients with ischemic cardiomyopathy.
Synapse has enriched 10 related papers. Consider them for comparative context: